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This study was performed to assess the efficacy and safety of a topical diclofenac solution in patients with knee osteoarthritis (OA).
PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases were searched for randomized controlled trials until
June 2020. The WOMAC pain, stiffness, physical function subscales, pain on walking, and the occurrence of adverse events were
pooled to comprehensively analyse the efficacy and safety of topical diclofenac solution. All statistical analyses were conducted
using Review Manager 5.3 software. Five RCTs were included, which provided high-quality evidence. In comparison to the
vehicle control, the mean differences for WOMAC pain, stiffness, and physical function subscales, as well as pain on walking,
were all statistically significant in favor of topical diclofenac solution. The safety of topical diclofenac solution was similar to the
vehicle control, apart from adverse events involving application-site skin reactions. Topical diclofenac solution is effective and
safe for use in patients with knee OA, but may cause minor skin reactions.
1. Introduction
Osteoarthritis (OA) is a highly prevalent degenerative joint
disease, which can cause chronic pain and disability that sig-
nificantly affect quality of life and the ability to perform daily
activities. It has been reported that one in eight adults has
osteoarthritis above 65 years of age [1]. Chronic OAmanage-
ment creates severe burdens for global healthcare systems
and negative impacts on work productivity [2–5]. Depending
on the stage of disease, treatment may range from conserva-
tive approaches to surgery for removing the joint. Current
conservative management approaches for knee OA include
extracorporeal shock wave [6], chondroitin sulfate [7], hya-
luronic acid [8], and nonsteroidal anti-inflammatory drugs
(NSAIDs) [9, 10]. Various complementary treatments have
also been tested including acupuncture [11], Baduanjin exer-
cises [12, 13], and herbal medicines [14, 15].
Among these conservative therapies, topical NSAIDs are
strongly recommended for knee OA patients (level 1A) with
no comorbidities, which have shown modest benefits over a
course of 12 weeks according to high-quality evidence [16].
Also, topical NSAIDs are also strongly recommended for
knee OA patients with gastrointestinal or cardiovascular
comorbidities, as well as for patients with frailty. Topical
diclofenac solution is one of the commonly used topical
NSAIDs, which is a cutaneous solution (1.5% w/w or 2% w
/w diclofenac sodium) indicated for the symptomatic relief
of pain associated with knee OA, and is currently approved
in Canada and several European countries. The solution base
contains dimethyl sulfoxide (DMSO) to enhance the absorp-
tion of diclofenac sodium [17–19], which is applied directly
to the affected knee.
In the current literature, one systematic review of ran-
domized controlled trials (RCTs) had evaluated the efficacy
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and safety of topical diclofenac solution when used to treat
knee OA [20], but did not include the more recent RCTs
[21, 22]. A network meta-analysis also compared the relative
efficacy and safety of topical diclofenac solution with another
11 topical NSAIDs [23], but this study did not include the
outcomes on Western Ontario and McMaster Universities
Arthritis Index (WOMAC) subscales and pain on walking.
Recently, a study on individual patient data meta-analysis
of RCTs showed that topical NSAIDs were effective for OA
pain relief, and that people with higher OA pain at baseline
experienced greater overall reductions in pain, although this
may have been attributed to contextual or nonspecific, rather
than specific, treatment effects [24]. The purpose of this
study was to perform a meta-analysis using the currently
available evidence from RCTs to investigate the efficacy and
safety of using topical diclofenac solution in patients with
knee OA.
2. Materials and Methods
2.1. Literature Search and Selection. Systematic literature
searches were performed using the PubMed, Embase,
Cochrane Library, Web of Science, and Scopus databases by
two independent researchers (T.L. and B.W.). Publications
were searched from January 1966 to June 2020, and studies
were limited to RCTs in patients with knee OA. The search
strategy included key search terms: (“Nonsteroidal Anti-
Inflammatory Agents” or “NSAIDs” or “diclofenac” or
“Pennsaid”) and (“Topical Administrations” or “Topical”)
and (“Osteoarthritis” or “Degenerative Arthritis” or “OA”).
The search filters were applied on “randomized controlled
trial” or “RCT.”We used Google Scholar to increase the abil-
ity to identify all literature related to the topic of interest ade-
quately. A systematic literature review was conducted by
browsing abstracts of major conferences to identify the addi-
tional unpublished studies. In addition, the reference lists of
previously published randomized trials, review articles, and
meta-analysis were manually searched for additional eligible
studies. Related articles and reference lists were searched to
avoid misses.
All citations were downloaded into Endnote X9.1 (Clari-
vate Analytics). Duplicate records were removed electroni-
cally and manually. Two authors (Tao Ling and Bin Wang)
screened the remaining articles at the title and abstract level
followed by full text. In addition, the reference list of relevant
systematic reviews and meta-analysis was scanned to identify
potentially eligible studies. Citations were exported to End-
note, and duplicates were removed before the titles and
abstracts, and the full text of remaining studies was then
assessed according to the inclusion and exclusion criteria.
The study protocol was registered with PROSPERO, number
CRD42020186646.
2.2. Inclusion and Exclusion Criteria. The inclusion criteria
for this meta-analysis: (1) studies involving patients with
knee OA; (2) RCTs; (3) interventions were topical diclofenac
solution and vehicle-placebo; (4) studies reporting outcomes
onWOMAC and adverse events; and (5) studies published in
English. The exclusion criteria for this meta-analysis: (1) sec-
ondary analyses, including pooled analyses; (2) study dura-
tion of less than 2 weeks; (3) studies involving multiple
pharmacological interventions; and (4) unavailable full text.
2.3. Study Quality Assessment. The WOMAC LK3.0 osteoar-
thritis index was used, and pain on walking was analyzed as a
separate efficacy variable [25, 26]. The Cochrane risk of bias
assessment tool was used to determine the methodological
quality of included RCTs [27]. A total of six domains were
evaluated: random sequence generation, allocation conceal-
ment, participant blinding, outcome assessor blinding,
incomplete outcome data, and selective reporting. Each
domain was assigned a judgment of low risk of bias, high risk
of bias, or unclear risk of bias. The judgments for each
domain were made by strictly following the Cochrane Hand-
book V.5.1.0, Chapter 8.5.
2.4. Statistical Analysis. For the assessment of efficacy, the
primary variable was changed in theWOMAC subscale score
for pain. The secondary variables were changes in the
WOMAC subscale scores for physical function and stiffness,
as well as the pain on walking. All changes resulted from
comparisons between baseline values and final assessment.
A meta-analysis was conducted to compare the efficacy and
safety of topical diclofenac solution with vehicle control.
The heterogeneity of the effect size across the included stud-
ies was tested using the Q statistic (P < 0:05 was considered
heterogeneous) and I2 statistic (I2 > 50% was considered het-
erogeneous). If there was no significant heterogeneity
between studies, a fixed-effects model was used; otherwise,
a random-effects model was used. Publication bias was
assessed using visual inspection of funnel plots, where an
asymmetrical funnel plot indicated potential publication bias
[28]. We assessed funnel plot asymmetry using Bgger’s tests,
and defined significant publication bias as a P value < 0·05.
All statistical analyses were conducted using ReviewManager
5.3 software (RevMan 5.3, Cochrane Collaboration, Oxford,
UK).
3. Results
3.1. Study Selection and Characteristics of Included Studies.
Of the 2073 studies identified from database searches, five tri-
als [21, 22, 29–31] involving 1271 knee OA patients were
included for data analysis. The characteristics and adverse
events reported in the included RCTs were presented in
Table 1. The experimental group was a topical diclofenac
solution, and the control group was vehicle control. The aver-
age age of patients was 62:84 ± 10:35 (mean ± standard
deviation) years, and 63.63% of patients were women. All tri-
als were conducted in USA or Canada, and the mean trial
duration was 7.6 weeks. The selection process for included
studies was shown in a flow diagram (Figure 1). The risk of
bias assessment showed that with the exception of one study
[22], all included studies had a low risk of bias for all of the
assessment criteria (Figure 2). The overall quality of the
included studies was high.
3.2. Efficacy of Topical Diclofenac Solution. A complete effi-
cacy profile analysis including the WOMAC pain subscale,

































































































































































































































































































































































































































































































































































































































































































the WOMAC physical function subscale, the WOMAC stiff-
ness subscale, and pain on walking was performed for all tri-
als selected for inclusion in this meta-analysis (Figure 3).
Topical diclofenac solution showed significant differences
compared to vehicle control, where results are shown by
mean differences (MD) and confidence interval (CI):
WOMAC pain subscale (MD= −1:42; 95% CI -1.91 to
-0.93; P < 0:0001), WOMAC physical function subscale
(MD= −4:64; 95% CI -6.25 to -3.03; P < 0:0001), WOMAC
stiffness subscale (MD= −0:54; 95% CI -0.75 to -0.32; P <
0:0001), and pain on walking (MD= −0:36; 95% CI -0.52 to
-0.20; P < 0:0001). Results of the WOMAC pain, physical
function and stiffness subscales, and the pain on walking
showed no heterogeneity: (I2 = 0%; P = 0:78), (I2 = 0%; P =
0:62), (I2 = 0%; P = 0:53), and (I2 = 0%; P = 0:86), respec-
tively. Funnel plots of the efficacy of topical diclofenac solu-
tion were shown in Figure 4. P values from Bgger’s test
indicated that there was no significant publication bias for
the WOMAC pain, stiffness, physical function subscales, or
pain on walking (P = 1:000, P = 0:806, P = 0:806, and P =
0:296, respectively).
3.3. Safety of Topical Diclofenac Solution. The meta-analysis
of the safety of topical diclofenac solution compared to
vehicle control is presented (Figure 5). There was a statis-
tically significant difference in the occurrence of adverse
events relating to application-site skin reactions between
the topical diclofenac solution and vehicle control groups
(OR = 1:71; 95% CI 1.31 to 2.23; P = 0:0001), and no het-
erogeneity was identified (I2 = 4%; P = 0:37). There were
no statistical differences in the occurrence of adverse events
relating to gastrointestinal tract reactions (OR = 0:99; 95%
CI 0.54 to 1.82; P = 0:97) or other reactions such as asthma
and dizziness (OR = 1:08; 95% CI 0.78 to 1.51; P = 0:72), with
moderate (I2 = 53%; P = 0:10) and no (I2 = 7%; P = 0:36) het-
erogeneity identified in these analyses, respectively. Funnel
plots of the safety of topical diclofenac solution were shown
in Figure 6. P values from Bgger’s test indicated that there
was no significant publication bias for the occurrence of
adverse events relating to application-site skin, gastroin-
testinal tract, or other reactions (P = 0:308, P = 0:734,
and P = 0:308, respectively). Pooled analysis of specific
adverse events relating to application-site skin reactions
showed that dry skin had significantly higher occurrence
rates for topical diclofenac solution compared to vehicle
control, while paresthesia, rash, and pruritus had similar
occurrence rates in both groups (Figure 7). Dry skin
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Figure 1: Flow diagram for the identification of included studies.
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reaction in both groups compared to other types of
adverse reactions.
4. Discussion
Topical administration of medication is often preferred in
clinical practice due to the advantages of having a high local
drug concentration, good treatment effect, and convenient
application and has been recommended for use in the treat-
ment of knee OA [16, 32, 33]. For diclofenac sodium, topical
administration can avoid systemic exposure resulting from
oral medication, which reduces the occurrence rate of
adverse events [34–39]. This is particularly beneficial as it
reduces the risks associated with polypharmacy for OA
patients, the majority of whom are elderly individuals and
may have other comorbidities requiring oral medication.
Our meta-analysis of five RCTs comparing topical adminis-
tration of topical diclofenac solution and vehicle control for
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Low risk of bias
Unclear risk of bias
High risk of bias














































































































































































Figure 2: Risk of bias assessment for the included studies: (a) “Risk of bias” summary: review authors’ judgments about each risk of bias item
for each included study (b) “Risk of bias” graph: review authors’ judgments about each risk of bias item presented as percentages across all
included studies.
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the treatment of knee OA showed that topical diclofenac
solution was significantly more effective at symptom relief
according to the 3 WOMAC subscale scores and pain on
walking. The safety of topical diclofenac solution was compa-
rable to the vehicle control with a similar occurrence rate of
adverse events, except for application-site skin reactions
which were significantly higher in the topical diclofenac solu-
tion group. Dry skin was the most common type of reaction
Study or subgroup
Experimental
Mean SD Total Mean SD Total
Weight
IV, fixed, 95% Cl
Control Mean difference














































Test for overall effect: Z = 5.70 (P < 0.00001) 
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Test for overall effect: Z = 5.65 (P < 0.00001) 



















































Test for overall effect: Z = 4.82 (P < 0.00001) 
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Test for overall effect: Z = 4.37 (P < 0.0001) 
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Figure 3: Meta-analysis of the efficacy of topical diclofenac solution compared to vehicle control. (a) WOMAC pain subscale, (b) WOMAC
physical function subscale, (c) WOMAC stiffness subscale, and (d) pain on walking.
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in the topical diclofenac solution group, which also occurred
at a much higher rate than in the vehicle control group. These
findings are consistent with an earlier meta-analysis pub-
lished in 2006 [20], although this earlier analysis did not
include the more recent topical diclofenac solution trials
[21, 22], one of which was the only RCT on 2% w/w topical
diclofenac solution [22].
Other studies have compared topical diclofenac solution
with oral diclofenac in the symptomatic treatment of knee
OA. In an equivalence study, topical diclofenac solution
was shown to provide symptomatic relief to the same extent
as oral diclofenac, with increased occurrence of minor local
skin irritation (27%) but significantly reduced incidence of
severe gastrointestinal adverse events and abnormal values
in liver function tests [40]. Similar results were obtained in
another study, where topical diclofenac was shown to have
a higher incidence of dry skin (18.2%) but fewer digestive sys-
tem and laboratory abnormalities [21]. The study concluded
that topical diclofenac in DMSO was an effective treatment
option for knee OA with similar efficacy but improved toler-
ability compared to oral diclofenac. In general, 1.5% topical
diclofenac solution (19.3mg/40 drops, twice daily) and 2%
w/w topical diclofenac solution (40.4mg/2mL, twice daily)
provide a similar daily dose to oral diclofenac (75mg, twice
daily), with equivalent efficacy but significantly lower expo-
sure and hence fewer adverse events [21, 37, 40].
A few studies have compared topical diclofenac solution
with 1% w/w diclofenac sodium gel for treating knee OA. A
comparative subjective assessment study showed that 1.5%
w/w topical diclofenac solution had a number of characteris-
tics that were rated significantly better than 1% w/w diclofe-
nac sodium gel, such as “odor/smell” and “stickiness/
tackiness on knee,” and more patients preferred or highly
preferred topical diclofenac solution over 1% w/w diclofenac
sodium gel [41]. A network meta-analysis of topical NSAIDs
for OA treatment showed that diclofenac solution and diclo-
fenac gel had similar effects on pain relief and functional
improvement in RCTs compared to placebo [23]. The risk
of skin adverse effects was higher for diclofenac solution,
but the risk of gastrointestinal adverse effects and withdrawal
due to adverse effects were higher for diclofenac gel.
Since topical diclofenac solution is a cutaneous solution,
its indication for symptomatic pain relief in knee OA is based
on the ability for diclofenac sodium to be absorbed through



















































Figure 4: Funnel plots of the efficacy of topical diclofenac solution compared to vehicle control. (a) WOMAC pain subscale, (b) WOMAC
physical function subscale, (c) WOMAC stiffness subscale, and (d) pain on walking.
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the skin, which is enhanced by the presence of DMSO. Top-
ical diclofenac solution is suitable for application to the knee
joint due to the anatomical joint structure bounded by thin
tissue layers. Although topical diclofenac solution can be the-
oretically applied to relieve osteoarthritic pain in large, deep
joints covered by layers of muscle or other soft tissues, such
as the hip or spine, no data are currently available. High-
quality RCTs will need to be performed to evaluate the effi-
cacy of topical diclofenac solution in such applications,
which would depend on the efficiency of absorption into
the joint.
This meta-analysis has some limitations that should be
taken into consideration when interpreting the findings.
First, some of the included RCTs had limitations associated
with the reported outcomes. For instance, day 1 efficacy
scores may have been used instead of baseline scores for some
patients. Two of the trials had a duration of 4 weeks, which
may not allow adequate assessment of potential long-term
safety concerns, such as gastrointestinal adverse effects. Sec-
ond, there were limitations relating to the characteristics of
the included studies. Only one of the five included RCTs used
a 2% topical diclofenac solution while the other four used
1.5% w/w topical diclofenac solution, which limits the ability
to generalize the findings in this meta-analysis for all topical
diclofenac solution formulations. Furthermore, all of the
included studies were sponsored by the manufacturers of
topical diclofenac solution. Although all of these studies gen-

































Test for overall effect: Z = 3.95 (P < 0.0001) 
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Test for overall effect: Z = 0.00 (P = 1.00)









M-H, fixed, 95% Cl
Control Odds ratio







































Test for overall effect: Z = 0.47 (P = 0.64) 
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Figure 5: Meta-analysis of the safety of topical diclofenac solution compared to vehicle control (a) adverse events relating to application-site
skin reactions, (b) adverse events relating to gastrointestinal tract reactions, and (c) adverse events relating to other reactions.
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and publishing these studies should be considered. Finally,
there may be high-quality non-English studies that could
have influenced the outcomes of our meta-analysis, but were
excluded due to the selection criteria.
5. Conclusion
This meta-analysis showed that topical diclofenac solution
provided effective treatment for patients with knee OA and
achieved significantly better results compared to vehicle con-
trol when assessed by the WOMAC subscales for pain, phys-
ical function, and stiffness, as well as pain on walking. The
main adverse events during treatment were application-site
reactions, particularly dry skin. In summary, the available
evidence on the combined efficacy and safety of topical diclo-
fenac solution makes it a viable treatment option for symp-
tomatic relief in knee OA.
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Figure 6: Funnel plots of the safety of topical diclofenac solution compared to vehicle control. (a) Adverse events relating to




























Figure 7: Occurrence rates of specific adverse events relating to
application-site skin reactions #P < 0:05 compared to vehicle
control; ∗∗∗P < 0:001 compared to dry skin.
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